Comparative Pharmacology
Head-to-head clinical analysis: BRISTAGEN versus NEOMYCIN POLYMYXIN B SULFATES BACITRACIN ZINC HYDROCORTISONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRISTAGEN versus NEOMYCIN POLYMYXIN B SULFATES BACITRACIN ZINC HYDROCORTISONE.
BRISTAGEN vs NEOMYCIN & POLYMYXIN B SULFATES & BACITRACIN ZINC & HYDROCORTISONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bristagen (amikacin) is an aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis.
Neomycin, polymyxin B, and bacitracin are antibiotics that inhibit bacterial protein synthesis, disrupt cell membrane integrity, and interfere with cell wall synthesis, respectively. Hydrocortisone is a corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis.
1-2 mg/kg IM or IV every 8-12 hours; typical adult dose is 1 mg/kg every 8 hours.
Apply to affected area 3-4 times daily. Not for use in eyes.
None Documented
None Documented
2.5 hours (prolonged to 20-40 hours in renal impairment).
Neomycin: 2-3h (normal renal); polymyxin B: 4-6h (normal renal), prolonged to 2-3 days in renal impairment; bacitracin: ~1.5h after IM; hydrocortisone: 1.5-2h (plasma). Topical: systemic levels negligible.
Renal (90% unchanged via glomerular filtration); biliary/fecal excretion <10%.
Neomycin: >90% renal (unchanged) after parenteral; polymyxin B: ~60% renal (unchanged) over 72h; bacitracin: >90% renal (unchanged) after IM; hydrocortisone: hepatic metabolism, metabolites renally eliminated (<1% unchanged). Topical: negligible systemic absorption across intact skin (except bacitracin may be minimally absorbed).
Category C
Category A/B
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic